Key Takeaways ABBV is expanding its pipeline with over 20 early-stage deals across immunology, oncology and neuroscience. The $2.1 billion Capstan deal adds a first-in-class CAR-T therapy and proprietary RNA delivery platform. Acquisitions of ImmunoGen and Cerevel have diversified ABBV's portfolio across multiple therapeutic areas.AbbVie (ABBV) has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signin ...